Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 10,400 shares, a decline of 38.1% from the August 15th total of 16,800 shares. Approximately 0.0% of the company's shares are sold short. Based on an average trading volume of 104,800 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 104,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company's shares are sold short.
Wall Street Analyst Weigh In
Several brokerages have issued reports on ADAG. HC Wainwright dropped their price target on Adagene from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Leerink Partners began coverage on Adagene in a research note on Wednesday, August 6th. They issued an "outperform" rating and a $7.00 price target on the stock. Finally, Leerink Partnrs raised Adagene to a "strong-buy" rating in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $7.00.
Check Out Our Latest Stock Report on ADAG
Hedge Funds Weigh In On Adagene
An institutional investor recently bought a new position in Adagene stock. Marex Group plc purchased a new position in shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,000 shares of the company's stock, valued at approximately $47,000. Marex Group plc owned approximately 0.05% of Adagene at the end of the most recent quarter. 9.51% of the stock is currently owned by hedge funds and other institutional investors.
Adagene Price Performance
Shares of NASDAQ:ADAG traded down $0.02 during trading on Friday, reaching $2.05. 57,253 shares of the stock were exchanged, compared to its average volume of 98,240. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.29 and a quick ratio of 2.30. Adagene has a 1-year low of $1.33 and a 1-year high of $3.16. The stock has a fifty day moving average of $2.08 and a two-hundred day moving average of $1.86.
Adagene Company Profile
(
Get Free Report)
Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
Read More
Before you consider Adagene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.
While Adagene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.